Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations

Huellner, Martin W.; Appenzeller, Paula; Kuhn, Félix P.; Husmann, Lars; Pietsch, Carsten; Burger, Irene A.; Porto, Miguel; Delso, Gaspar; Schulthess, Gustav K. von; Veit-Haibach, Patrick

doi:10.1148/radiol.14140090

Cited by 78 publications

(115 citation statements)

References 18 publications

Supporting

Mentioning

112

Contrasting

Order By: Relevance

“…Despite limitations, most studies have found that the performance of PET/MRI is at least equivalent to, if not slightly better than, that of PET/CT (37,(49)(50)(51). PET/MRI appears to add data not provided by PET/CT, and these data can significantly affect patient management (42).…”

Section: Resultsmentioning

confidence: 99%

Evaluation of Prostate Cancer with PET/MRI

et al. 2016

View full text Add to dashboard Cite

In the ongoing effort to understand and cure prostate cancer, imaging modalities are constantly evolving to assist in clinical decisions. Multiparametric MRI can be used to direct prostate biopsies, improve diagnostic yield, and help clinicians make more accurate decisions. PET is superior in providing biologic information about the cancer and is sensitive and highly specific. Integrated PET/MRI is a welcome technical advance with great potential to influence the diagnosis and management of prostate cancer in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of Prostate Cancer with PET/MRI

et al. 2016

View full text Add to dashboard Cite

show abstract

“…For example, DWI based on a single-shot echo planar imaging (EPI) sequence often presented image distortion, which caused reduced quality of fusion images. Development of fusion-compatible MRI sequences will be helpful for increasing diagnostic accuracy [83][84][85].…”

Section: Consideration For Study Protocolmentioning

confidence: 99%

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

Kwon

Becker

Goo

et al. 2016

Nucl Med Mol Imaging

View full text Add to dashboard Cite

The recent advance in hybrid imaging techniques enables offering simultaneous positron emission tomography (PET)/magnetic resonance imaging (MRI) in various clinical fields. 18F-fluorodeoxyglucose (FDG) PET has been widely used for diagnosis and evaluation of oncologic patients. The growing evidence from research and clinical experiences demonstrated that PET/MRI with FDG can provide comparable or superior diagnostic performance more than conventional radiological imaging such as computed tomography (CT), MRI or PET/CT in various cancers. Combined analysis using structural information and functional/molecular information of tumors can draw additional diagnostic information based on PET/MRI. Further studies including determination of the diagnostic efficacy, optimizing the examination protocol, and analysis of the hybrid imaging results is necessary for extending the FDG PET/MRI application in clinical oncology.

show abstract

“…The PET data were acquired in 3D TOF mode with a scan duration of 2 min per bed position, an overlap of bed Images were filtered in image space using an in-plane Gaussian convolution kernel with a full-width at halfmaximum of 4.0 mm, followed by a standard axial filter with a three-slice kernel. This procedure has been used in this standard manner in other studies as well [17].…”

Section: F-fdgmentioning

confidence: 99%

“…Most of the protocols in such an early phase of a new modality are just 'normal' MR protocols that do not take into account the additional diagnostic information of the PET component. However, in our study, here, we evaluated a PET/MRI protocol that consists of three noncontrast sequences that allow for a whole-body PET/MRI approximately within the same time than a standard PET/CT [17].…”

Section: Generalmentioning

confidence: 99%

18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT

Samarin

Hüllner

Queiroz

et al. 2015

Nuclear Medicine Communications

Self Cite

View full text Add to dashboard Cite

PURPOSE: The aim of this study was to compare detection, lesion conspicuity and reader confidence of F-fluorodeoxyglucose (F-FDG)-PET/MR and F-FDG-PET/computed tomography (CT) in patients with F-FDG avid bone metastases. MATERIALS AND METHODS: In this prospective study, a total of 30 PET/CT and PET/MRI data sets were performed in 24 patients. Each examination was evaluated for the presence of PET-positive bone lesions consistent with metastatic involvement. Conspicuity of PET-positive bone lesions was evaluated on the corresponding PET/CT and PET/MR images and compared using the Wilcoxon signed-ranks test. Reader confidence was determined to evaluate whether PET/CT or PET/MR was more useful for the assessment of the bone metastases and was compared using Student's t-test. RESULTS: Overall, in both examinations, PET/CT and PET/MRI detected 86 F-FDG-positive bone lesions. On all 30 PET/MRI examinations, at least one morphological correlate for F-FDG-positive bone lesions was found on the MR component (82 out of 86 lesions). PET/CT imaging allowed identification of corresponding structural changes on the CT component in 23 out of 30 studies (65 out of 86 lesions). In lesion-by-lesion analysis, the mean lesion conspicuity was significantly better on T1 fat MR imaging compared with CT imaging (P=0.005). In seven out of 30 studies, a significant increase in reader confidence of PET/MRI compared with PET/CT was found. CONCLUSION: PET/MRI offers higher reader confidence and improved conspicuity in bone metastases compared with PET/CT. However, the overall detection rate was not different. The highest possible clinical impact of PET/MRI appears to be in patients with limited, early bone metastatic disease. Materials and methods In this prospective study, a total of 30 PET/CT and PET/MRI data sets were performed in 24 patients. Each examination was evaluated for the presence of PET-positive bone lesions consistent with metastatic involvement. Conspicuity of PET-positive bone lesions was evaluated on the corresponding PET/CT and PET/MR images and compared using the Wilcoxon signed-ranks test. Reader confidence was determined to evaluate whether PET/CT or PET/MR was more useful for the assessment of the bone metastases and was compared using Student's t-test. In lesion-by-lesion analysis, the mean lesion conspicuity was significantly better on T1 fat MR imaging compared with CT imaging (P = 0.005). In seven out of 30 studies, a significant increase in reader confidence of PET/MRI compared with PET/CT was found.Conclusion PET/MRI offers higher reader confidence and improved conspicuity in bone metastases compared with PET/CT. However, the overall detection rate was not different. The highest possible clinical impact of PET/MRI appears to be in patients with limited, early bone metastatic disease. Nucl Med Commun 00:000-000

show abstract

Whole-Body Nonenhanced PET/MR versus PET/CT in the Staging and Restaging of Cancers: Preliminary Observations

Abstract: PET/MR performs comparably to PET/CT in whole-body oncology and neoplastic lung disease, with the use of appropriate sequences. Further studies are needed to define regionalized PET/MR protocols with sequences tailored to specific tumor entities.

Cited by 78 publications

References 18 publications

Evaluation of Prostate Cancer with PET/MRI

Evaluation of Prostate Cancer with PET/MRI

FDG Whole-Body PET/MRI in Oncology: a Systematic Review

18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT

Contact Info

Product

Resources

About